Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty.

Kristen Sparrow • June 23, 2019

This is an important part of the conversation about aging.  Of course, stress reduction to reduce overall inflammation is what I pay attention to in the clinic by monitoring HRV.  There is a full article here
2018 Sep;15(9):505-522. doi: 10.1038/s41569-018-0064-2.

Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty.

Author information

Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, MD, USA.
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.


Most older individuals develop inflammageing, a condition characterized by elevated levels of blood inflammatory markers that carries high susceptibility to chronic morbidity, disability, frailty, and premature death. Potential mechanisms of inflammageing include genetic susceptibility, central obesity, increased gut permeability, changes to microbiota composition, cellular senescence, NLRP3 inflammasome activation, oxidative stress caused by dysfunctional mitochondria, immune cell dysregulation, and chronic infections. Inflammageing is a risk factor for cardiovascular diseases (CVDs), and clinical trials suggest that this association is causal. Inflammageing is also a risk factor for chronic kidney disease, diabetes mellitus, cancer, depression, dementia, and sarcopenia, but whether modulating inflammation beneficially affects the clinical course of non-CVD health problems is controversial. This uncertainty is an important issue to address because older patients with CVD are often affected by multimorbidity and frailty – which affect clinical manifestations, prognosis, and response to treatment – and are associated with inflammation by mechanisms similar to those in CVD. The hypothesis that inflammation affects CVD, multimorbidity, and frailty by inhibiting growth factors, increasing catabolism, and interfering with homeostatic signalling is supported by mechanistic studies but requires confirmation in humans. Whether early modulation of inflammageing prevents or delays the onset of cardiovascular frailty should be tested in clinical trials.